Investment Rating - The industry investment rating is maintained at "Overweight" [2][8]. Core Insights - The vaccine industry is undergoing a transformation from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term growth logic remains intact, driven by policy, demand, and technology [8][25]. - Recent developments in vaccine research and international expansion signal positive trends, with a shift in focus from child vaccination to a broader lifecycle approach due to demographic changes [3][7]. Summary by Sections Industry Performance - The vaccine sector has seen a relative performance decline of 25% over the past 12 months compared to the CSI 300 index, with absolute returns down by 2% [3]. - The vaccine index rose by 0.49% in the last week, while the overall pharmaceutical sector declined by 0.39% [4][5]. Company Developments - Huashan Vaccine received approval for clinical trials of its recombinant shingles vaccine [3]. - Kanghua Bio announced a projected net profit decline of 41.55%-52.09% for 2025, primarily due to decreased vaccine sales and market competition [3]. - Kexing Bio secured a two-year exclusive order for hepatitis A vaccine in Oman, marking a significant breakthrough in the Middle East market [3]. - Aimee Vaccine's 20-valent pneumococcal polysaccharide conjugate vaccine has been approved for clinical trials [3]. Market Dynamics - The industry is experiencing a shift in demand dynamics, with a notable decrease in newborn population affecting vaccine demand negatively, necessitating a re-evaluation of growth strategies [3][7]. - The vaccine sector's price competition is intensifying due to a high proportion of Me-too products, leading to significant price drops for some vaccines [7][22]. Valuation Metrics - The vaccine sector's PE (ttm) stands at 93.89X, with a PB (lf) of 1.82X, indicating a slight increase in valuation metrics compared to previous periods [6][18]. Investment Recommendations - The report suggests focusing on companies with strong innovation capabilities and differentiated product lines, particularly those with high technical barriers and international market strategies [8][25]. - Long-term investment opportunities are seen in companies that can leverage innovation and international expansion to navigate current market challenges [7][8].

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints - The report analyzes the market and ETF performance in the past week, and recommends industries and ETFs to focus on next week based on the PB - ROE framework and the ETF redemption sentiment indicator model [8][36] 3. Summary by Directory 3.1 Recent Market Overview (January 19 - 23, 2026) - Among the 31 Shenwan primary industries, 24 rose and 7 fell. The top three gainers were building materials (up 9.23%), petroleum and petrochemicals (up 7.71%), and steel (up 7.31%); the top three losers were banks (down 2.70%), communications (down 2.12%), and non - bank finance (down 1.45%) [4][11] - The Shanghai Composite Index closed at 4136.16, up 0.84% for the week; the Shenzhen Component Index closed at 14439.66, up 1.11% for the week; the ChiNext Index closed at 3349.50, down 0.34% for the week; the Beixin 50 Index closed at 1588.66, up 2.60% for the week; the Hang Seng Index closed at 26749.51, down 0.36% for the week. The average daily trading volume of the Shanghai and Shenzhen stock markets was 27727.12 billion yuan, and the total trading volume for the week was 13.86 trillion yuan [11] - Main funds had net outflows on 4 trading days and net inflows on 1 trading day, with a total net outflow of 125.207 billion yuan for the week. The industries with more net inflows of main funds were banks, non - bank finance, and non - ferrous metals; the industries with more net outflows were electronics, communications, and computers [4][11] 3.2 Recent ETF Market Performance (January 19 - 23, 2026) 3.2.1 Stock - type ETFs - 8 new stock - type ETFs were listed, including 2 battery ETFs and 6 other stock - type ETFs. 9 new ETFs were established, including 2 Shanghai - STAR Market chip ETFs and 7 other ETFs, with a total issuance scale of 4.416 billion yuan [5][18] - The median weekly increase or decrease of stock - type ETFs was 0.88%. Gold stock ETFs and photovoltaic leading ETFs performed well, with gold stock ETFs rising the most (13.17%); science and innovation semiconductor ETFs and financial real - estate ETFs performed poorly, with science and innovation semiconductor ETFs falling the most (3.86%) [5][21] - The average weekly share change of stock - type ETFs was a decrease of 51.8174 million shares. Chemical ETFs and power grid equipment ETFs had more share increases, with chemical ETFs increasing the most (6.316 billion shares); CSI 300ETF and SSE 50ETF had more share decreases, with Huatai - Ber瑞 CSI 300ETF decreasing the most (15.345 billion shares) [21] 3.2.2 Bond - type ETFs - The median weekly increase or decrease of 53 bond - type ETFs was 0.11%. Convertible bond ETFs had the highest increase (2.94%), and treasury bond ETFs had the lowest increase (0.01%). As of January 23, 2026, the scale of Haifutong CSI Short - term Financing ETF (511360.SH) was the largest, at 70.223 billion yuan [24] 3.2.3 Cross - border ETFs - The median weekly increase or decrease of cross - border ETFs was - 0.66%. The Brazilian ETF and the S&P Biotechnology ETF had high increases or decreases, with the Brazilian ETF rising the most (7.63%); the Hong Kong Stock Connect Innovative Drug ETF and the Hong Kong Innovative Drug ETF had low increases or decreases, with the Hong Kong Stock Connect Innovative Drug ETF falling the most (3.94%) [26] - Since the beginning of the year, the median increase or decrease of cross - border ETFs has been 3.84%. The China - South Korea Semiconductor ETF and the Hong Kong Medical ETF had high increases, with the China - South Korea Semiconductor ETF rising 23.87%; the Nasdaq ETF and the Nasdaq Technology ETF had high decreases, with the Nasdaq Technology ETF falling 2.79% [26] 3.3 PB - ROE Framework - based ETF Rotation Strategy Tracking - The strategy focuses on the communications, agriculture, forestry, animal husbandry, and fishery, and transportation industries, corresponding to their respective industry ETFs. This week, the strategy's cumulative return was 1.29%, the CSI 300 Index's cumulative return was - 0.62%, and the strategy's cumulative excess return relative to the CSI 300 Index was 1.91% [7][31] - Since 2023, the strategy's cumulative return has been 27.65%, the CSI 300's cumulative return has been 21.46%, and the strategy's cumulative excess return relative to the CSI 300 Index has been 6.19% [7][33] - Since 2022, the strategy's cumulative return has been 9.16%, the CSI 300's cumulative return has been - 4.81%, and the strategy's cumulative excess return relative to the CSI 300 Index has been 13.98% [35] 3.4 Investment Recommendations - Based on industry PB - ROE and supplementary indicators, the PB - ROE framework - based ETF rotation strategy recommends focusing on the communications, agriculture, forestry, animal husbandry, and fishery, and transportation industries next week, corresponding to their respective industry ETFs [8][36] - According to the ETF redemption sentiment indicator model, it is recommended to focus on breeding ETFs, satellite ETFs, pharmaceutical ETFs, securities ETFs, and science and innovation AI ETFs next week [8][36]

Industry and Company Overview - The medical consumables industry is undergoing significant changes with the recent announcement of the sixth batch of national high-value medical consumables centralized procurement, which took place on January 13, 2026. This procurement includes 12 types of medical consumables, with 496 products from 227 companies bidding, and 440 products from 202 companies selected [2][4]. - The procurement process emphasizes principles such as "stabilizing clinical use, ensuring quality, preventing internal competition, and avoiding collusion." This includes grouping products based on demand and supply capabilities to ensure that clinically recognized and capable products are selected [4]. Procurement Results and Implications - The results of the procurement are expected to be implemented by May 2026, allowing patients to access more reasonably priced and quality-assured products. The inclusion of drug-coated balloons and urological intervention consumables marks a significant step in addressing previously unaddressed areas in procurement [4]. - The procurement rules have been optimized to discourage traditional low-price competition strategies, pushing companies to focus on clinical value, supply stability, and innovation. This creates a more favorable environment for both large and small enterprises, particularly those with innovative products [4]. Investment Recommendations - The medical consumables industry, particularly high-end implantable devices such as orthopedic implants, cardiovascular intervention devices, and neurosurgical implants, is expected to benefit from policy support. The optimized procurement rules are likely to stabilize expectations and mitigate low-price competition [5]. - Companies with strong cost control, continuous innovation capabilities, and those that can achieve market share growth through domestic substitution are recommended for investment. Specific attention should be given to companies with product advantages in rehabilitation and chronic disease management [5].

证券研究报告 2026 年 01 月 21 日 湘财证券研究所 策略研究 策略月报 2 月热点或将延续 1 月的科技、有色等方向 ——2026 年 02 月 A 股策略 率窄幅震荡》 2025.11.25 证书编号：S0500519120001 Tel：(8621) 50295323 Email：qh3062@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点： 相关研究： 2026 年宏观短周期和中周期有望形成向上共振格局 1. 《20251125湘财证券-策略研 究-12月等待政策定调，市场大概 2. 《20251222湘财证券-策略研 究-1月市场大概率继续窄幅震荡》 2025.12.22 我们预判 2026 年宏观中周期和宏观短周期均处于底部反弹的阶段，有望形 成向上共振格局。具体原因有：一是海外方面，中美贸易冲突缓和，有助于 减轻经济下行压力。二是"十五五"规划即将落地，新质生产力依然是重要 发展方向，随着人工智能等科技领域的快速发展，将有效推动我国产业升级。 三是 2025 年 12 月中央经济工作会议定调 2026 年宏观政策为继续实施更加 积极的财政政策、适度 ...

Industry and Company Overview - The home appliance industry experienced a decline of 0.34% this week, with the home appliance components sub-industry leading the gains [2] - The home appliance industry ranks 16th among 31 industries in the Shenwan classification, while the CSI 300 index declined by 0.57% during the same period [2] - The top five gainers in the home appliance sector this week were Tianyin Electromechanical (+41.20%), Lek Electric (+21.13%), Zhaochi Co. (+18.58%), *ST Gauss (+10.61%), and Hesheng New Materials (+10.37%) [2] Valuation Insights - As of January 16, the price-to-earnings ratio (PE-ttm) for the home appliance industry is 15.63 times, ranking 25th among 31 Shenwan industries [3] - The PE ratio for the CSI 300 index is 13.50 times, indicating that the home appliance industry's valuation is relatively low [3] - The valuation percentile for the home appliance industry is 39.2%, further highlighting its investment attractiveness compared to the CSI 300 index's 84.4% [3] Smart Kitchen Appliances Focus - Boss Electric announced a capital increase of 100 million RMB in Youte Smart Kitchen, aiming to deepen its involvement in the cooking robot sector [4] - The cooking robot industry is rapidly expanding, with the Chinese market expected to reach 3.7 billion RMB by 2025 and exceed 11.7 billion RMB by 2030 [4][5] - Global cooking robot market is projected to grow from 4.01 billion USD in 2025 to 12.37 billion USD by 2035, with a CAGR of 11.92% [5] Investment Recommendations - The home appliance industry is transitioning from incremental competition to stock integration, with a focus on efficiency optimization, product innovation, and technological upgrades [6] - Three main investment themes are recommended for 2026: 1. Focus on white goods leaders with solid market positions, improved operational efficiency, and high dividend yields during the industry downturn [6] 2. Identify niche sectors that can explore new demands through new products and technologies, such as kitchen robots and smart home devices [6] 3. Look for opportunities driven by "trade-in" policies and upgrades in AI and smart home industries [6] - The overall rating for the home appliance industry is maintained at "overweight" [6]

Investment Rating - The industry investment rating is maintained as "Buy" [2] Core Insights - The macroeconomic and consumption environment shows signs of marginal improvement despite ongoing pressure in the consumer market. The restaurant sector continues to outperform overall retail sales, indicating structural growth opportunities for the beer industry [4][14] - The beer industry is experiencing a seasonal production decline due to the off-peak season, but overall production levels remain stable compared to previous years. The industry is expected to recover, with a focus on high-end and super high-end beer segments [5][36] - Cost pressures in the beer industry are manageable, with stable raw material costs and a neutral overall cost environment. Price stability in the terminal market supports profitability [6][50] Summary by Sections 1. Macroeconomic and Consumption Environment - In December 2025, the retail sales growth rate fell to 0.9% year-on-year, while the restaurant sector showed a 2.2% increase, indicating resilience in selected consumption categories. CPI rose to 0.8%, and PPI showed a narrowing decline at -1.9% [4][14] - Consumer confidence and income indicators are gradually improving, which is expected to enhance consumption potential in 2026 [15][16] 2. Overall Operation of the Beer Industry - December 2025 saw a seasonal decline in beer production, with a total production of 331.81 million hectoliters by the end of November. The industry is expected to maintain production levels close to historical highs despite short-term fluctuations [5][33] - The import and export dynamics show a weak import performance but stable export growth, with expectations for marginal improvement in imports in early 2026 [34][35] 3. Prices and Costs - Raw material costs remain stable, with domestic barley prices at 2205 CNY/ton and imported barley prices at 255 USD/ton. Packaging material costs are in a neutral state due to price fluctuations [6][49] - The terminal prices for canned and bottled beer have shown minimal fluctuations, maintaining a stable pricing structure [50][51] 4. Tracking of Listed Companies - The stock prices of key beer companies in the A-share and Hong Kong markets have shown slight declines, with most companies experiencing negative growth. Market sentiment appears cautious [58][61] 5. Investment Recommendations - Despite ongoing declines in retail sales data, the beer sector is positioned for potential valuation recovery due to low historical valuation levels. The expected improvement in consumer confidence and manageable cost pressures supports a positive outlook for the beer industry in 2026 [9][67]

Macro Commentary and Market Analysis - Recent macro data shows a rebound in exports with a year-on-year growth rate of 6.6% in December, up from 5.90% in November, leading to an annual cumulative growth rate of 5.50% [2][3] - M2 growth in December was 8.50%, expected to remain around 8% in 2025, indicating a "moderately loose" monetary policy that supports economic recovery [3] - M1 growth was only 3.80% in December, reflecting weak investment and consumption willingness among enterprises and residents [3] - M0 saw a significant increase of 10.2% in December, indicating strong cash demand and active payment activities [3] Industry and Company Analysis - The securities industry experienced a slight decline, with the brokerage index down 2.2%, underperforming the CSI 300 index by 1.6 percentage points [12] - The average daily stock trading volume reached 34,283 billion yuan, a 21.2% increase week-on-week, marking a historical high [13] - The financing scale for equity financing reached 1,113 billion yuan, with significant contributions from large-scale placements [14] - The current PB valuation of the brokerage index is 1.38x, which is at the 35th percentile of the last decade, indicating a low valuation relative to expected earnings growth [12][15] Investment Recommendations - The report suggests maintaining an "overweight" rating on the securities industry, highlighting the potential for valuation recovery due to favorable regulatory policies and increasing trading activity [15] - Focus is recommended on internet brokerages with strong beta attributes and firms with solid earnings certainty in an active market environment [15]

Investment Rating - The industry rating is maintained at "Overweight" [7][36] Core Views - The recent structural policy tool interest rate cut aims to stabilize bank funding costs, with a reduction in various relending rates from 1.5% to 1.25% and an increase in the scope and amount of structural tools [6][33] - The total relending quota for supporting agriculture and small enterprises has been increased by 500 billion yuan, with a separate quota of 1 trillion yuan for private enterprises [33] - The relending quota for technological innovation and transformation has been raised by 400 billion yuan to 1.2 trillion yuan, expanding support to private SMEs with high R&D investments [33] - The balance of structural policy tools is expected to be 5.9 trillion yuan by March 2025, with the interest rate cut of 0.25% anticipated to impact commercial banks' funding costs by approximately 0.4 basis points [33] Summary by Sections Market Review - The banking index has decreased by 3.03% from January 12, 2025, to January 18, 2026, underperforming the CSI 300 index by 2.46 percentage points [11] - The performance of different bank categories shows large banks down by 2.20%, joint-stock banks down by 4.08%, city commercial banks down by 2.40%, and rural commercial banks down by 2.20% [11] Investment Recommendations - The report suggests focusing on state-owned banks with stable asset deployment and joint-stock and regional banks with growth potential amid economic recovery [9][36] - Recommended banks include Industrial and Commercial Bank of China, Bank of China, CITIC Bank, Jiangsu Bank, Shanghai Rural Commercial Bank, Chongqing Rural Commercial Bank, and Suzhou Bank [9][36]

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The medical consumables sector saw a slight increase of 0.62% last week, while the broader pharmaceutical and biological sector decreased by 0.68% [4] - The current Price-to-Earnings (PE) ratio for the medical consumables sector is 37.38X, with a Price-to-Book (PB) ratio of 2.69X [5][16] - The sixth batch of national high-value medical consumables procurement opened on January 13, 2026, involving 12 types of medical consumables with 227 companies participating [6][19] Industry Performance - Over the past month, the medical consumables sector has shown a relative return of 6%, while the absolute return over the last 12 months is 19% [3] - The sector's performance compared to the CSI 300 index indicates a slight underperformance of 0.11 percentage points last week [4][9] Industry Dynamics and Company Announcements - The recent procurement rules emphasize clinical value and innovation over low pricing, which may benefit small and medium enterprises by providing a survival and growth space [6][22] - The procurement results are expected to be implemented by May 2026, allowing patients to access reasonably priced and quality-assured products [20][22] Investment Recommendations - The report suggests focusing on leading companies with strong cost control and innovation capabilities, particularly in the fields of rehabilitation and chronic disease management [7][23] - Recommended companies include those with rich product lines and high innovation levels, such as Huatai Medical and Weier Medical, as well as orthopedic consumables companies like Weigao Orthopedics [7][23]

Investment Rating - The industry investment rating is maintained at "Overweight" [3][44]. Core Insights - The rare earth magnetic materials industry has shown a strong performance, with a 2.95% increase this week, outperforming the benchmark (CSI 300) by 3.52 percentage points [5][12]. - The valuation of the industry (TTM P/E) has rebounded to 82.16x, currently at the 91.5% historical percentile [5][12]. - The prices of rare earth concentrates have expanded, with significant increases in praseodymium and neodymium prices, while dysprosium and terbium prices have shown fluctuations [6][9][19]. - The supply side of rare earths is tight, with limited availability of oxides, while the demand remains stable, indicating that prices are expected to remain strong in the short term [42][43]. Summary by Sections Industry Performance - Over the past month, the industry has shown a relative return of 13%, a 3-month return of -4%, and a 12-month return of 65% [4]. - Absolute returns for the same periods are 18%, -1%, and 90% respectively [4]. Price Trends - Domestic mixed rare earth carbonate prices increased by 9.3%, while prices for Sichuan and Shandong fluorocarbon cerium ores rose by 7.89% and 9.09% respectively [9][12]. - The average price of praseodymium oxide rose by 8% to 675,000 CNY/ton, and the average price of praseodymium metal increased by 7.06% to 811,000 CNY/ton [16][19]. - The average price of neodymium-iron-boron sintered blocks increased by 9.36% for N35 and 6.38% for H35 [38]. Investment Recommendations - The report suggests continued focus on upstream rare earth resource companies due to market sentiment recovery and strategic value positioning [44]. - Downstream magnetic material companies are expected to see profit recovery as rare earth prices rise, with a recommendation to pay attention to companies with strong customer structures and future growth potential, such as Jinli Permanent Magnet [10][44].